Helix BioPharma Cash And Equivalents vs. Cash Flow From Operations

HBPCFDelisted Stock  USD 0.15  0.00  0.00%   
Based on the key profitability measurements obtained from Helix BioPharma's financial statements, Helix BioPharma Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in June. Profitability indicators assess Helix BioPharma's ability to earn profits and add value for shareholders.
For Helix BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Helix BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Helix BioPharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Helix BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Helix BioPharma Corp over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Please note, there is a significant difference between Helix BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Helix BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Helix BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Helix BioPharma Corp Cash Flow From Operations vs. Cash And Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Helix BioPharma's current stock value. Our valuation model uses many indicators to compare Helix BioPharma value to that of its competitors to determine the firm's financial worth.
Helix BioPharma Corp is rated below average in cash and equivalents category among related companies. It is rated # 4 in cash flow from operations category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Helix BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Helix BioPharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Helix BioPharma's earnings, one of the primary drivers of an investment's value.

Helix Cash Flow From Operations vs. Cash And Equivalents

Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Helix BioPharma

Cash

 = 

Bank Deposits

+

Liquidities

 = 
1.88 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Helix BioPharma

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(6.51 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Helix Cash Flow From Operations Comparison

Helix BioPharma is currently under evaluation in cash flow from operations category among related companies.

Helix BioPharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Helix BioPharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Helix BioPharma will eventually generate negative long term returns. The profitability progress is the general direction of Helix BioPharma's change in net profit over the period of time. It can combine multiple indicators of Helix BioPharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. HELIX BIOPHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.

Helix Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Helix BioPharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Helix BioPharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Helix BioPharma's important profitability drivers and their relationship over time.

Use Helix BioPharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.

Helix BioPharma Pair Trading

Helix BioPharma Corp Pair Trading Analysis

The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Helix BioPharma position

In addition to having Helix BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aggressive Defence Thematic Idea Now

Aggressive Defence
Aggressive Defence Theme
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Helix BioPharma Corp information on this page should be used as a complementary analysis to other Helix BioPharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in Helix Pink Sheet

If you are still planning to invest in Helix BioPharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Helix BioPharma's history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets